GermanyGermany

Wilex finds US commercialisation partner for Rencarex

03.05.2011

Munich/San Diego – German Wilex has sold the exclusive US marketing rights for RENCAREX® (girentuximab), its Phase III monoclonal antibody for adjuvant use in non-metastatic clear-cell renal cell cancer (ccRCC) to Prometheus Laboratories Inc. Under the terms of the agreement, Wilex will receive $19.0 million upfront, development fees, plus milestone payments and royalties on U.S. net sales of the chimeric monoclonal antibody that targets the CA IX-antigen, which is overexpressed on 95% of ccRCC and various other solid tumours. Additionally, Wilex has options for commercialisation outside the United States to one of Prometheus' marketed products or additional cash payments of up to $20 million. With the deal, the US company, which has a track record of commercialisation of oncology products, strengthens its oncology pipeline. girentuximab is currently being tested in a Phase III trial versus placebo in the adjuvant setting in 864 patients with non-metastatic clear cell renal cell cancer at high risk of recurrence after nephrectomy. WILEX expects the results from the interim analysis for efficacy of girentuximab in the second half of 2011, which could form the basis for the European MAA.

GermanyGermany

12.06.2011

Düsseldorf/Cologne – XCell-Center GmbH has been under heavy public pressure since the death of an 18-month-old toddler last year that was apparently caused by one of their treatments. The child was given an injection of...

GermanyGermany

30.05.2011

Berlin – German researchers have found a major determinant of pluripotency in mouse cells. The findings are essential to understand how to regenerate cells for medical purposes and drug screening. In the EMBO Journal, the group...

GermanyGermany

19.05.2011

Hamburg/Basel – Evotec AG and its partner Roche have terminated the first proof-of-concept study with Evotec’s NR2B sub-type selective NMDA antagonist EVT 101 in treatment-resistant depression.The firms said the move was...

GermanyGermany

14.04.2011

Freising – German drug development pioneer Pieris AG will use its Anticalin scaffold technology to develop high affinity binders against two targets from Daiichi Sankyo Company Ltd (Tokyo). Pieris will receive EUR7 million...

GermanyGermany

11.04.2011

Berlin – Germany has begun to cross-link and to standardise its existing registries for medical human samples and data (so-called biobanks) at five locations, to make the promise of personalised medicine a reality. Each of the...

GermanyGermany

07.04.2011

Berlin – The German biotechnology industry is growing. German companies showed an increased turnover of a2.4bn (+9%) in 2010, record funding of a700m (+122%) and an increase in the number of employees in commercial biotechnology...

Displaying results 41 to 50 out of 454

< Previous 41-50 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/4/article/wilex-finds-us-commercialisation-partner-for-rencarex.html

Events

All Events

Stock list

All quotes

TOP

  • BIOINVENT INTERNATIONAL AB (S)3.10 SEK9.15%
  • Allergy Therapeutics (UK)19.12 GBP6.94%
  • PHARMING (NL)0.48 EUR6.67%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • CHRONTECH PHARMA (S)0.07 SEK-12.50%

TOP

  • WILEX (D)3.15 EUR314.5%
  • SANTHERA (CH)68.55 CHF90.4%
  • ADDEX (CH)4.08 CHF82.1%

FLOP

  • MERCK KGAA (D)65.43 EUR-48.6%
  • HYBRIGENICS (F)1.83 EUR-26.8%
  • PROSENSA (NL)9.48 USD-25.2%

TOP

  • SANTHERA (CH)68.55 CHF3489.0%
  • GW PHARMACEUTICALS (UK)427.00 GBP729.1%
  • PAION (D)2.79 EUR316.4%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • PROSENSA (NL)9.48 USD-68.0%

No liability assumed, Date: 25.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products